Detection method and use of Jieyuhegan pills prescription preparation
By employing high-performance liquid chromatography and a specific gradient elution procedure, the problem of incomplete detection of the prescription preparation of Jieyu Hegan Pill was solved, achieving the separation and localization of 21 characteristic peaks, improving the accuracy and speed of quality detection, and providing a basis for quality control.
Patent Information
- Application Number
- CN202211742129.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-30
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2042-12-30
AI Technical Summary
Existing technologies cannot comprehensively and systematically test the product quality of prescription preparations of Jieyu and Ganwan, resulting in insufficient quality control.
High-performance liquid chromatography (HPLC) was used with octadecylsilane-bonded silica gel as the packing material, acetonitrile as the mobile phase A, and 0.05–0.15% aqueous phosphoric acid solution as the mobile phase B. The components in the prescription preparation of Jieyu and Ganwan were separated by gradient elution program. Combined with specific test solution preparation method and fingerprint spectrum comparison, 21 characteristic peaks were detected and located.
This technology enables comprehensive and accurate quality testing of the prescription formulation of Yuhegan Pills, improves testing speed and efficiency, provides a basis for quality control, and allows for rapid and comprehensive monitoring of product quality.
Smart Images

Figure CN116465980B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicine detection, and in particular to a detection method and application of a Jieyuhegan pill prescription preparation, and further to a detection method and application of a Jieyuhegan pill prescription preparation, a quality control method of the Jieyuhegan pill prescription preparation and a content determination method of the Jieyuhegan pill prescription preparation. Background Art
[0002] The prescription of Jieyuhegan Pills comes from the "Selected Chinese Medicine Formulas of Beijing", which is now included in the "Volume 8 of the Standard Chinese Medicine Formulas of the Ministry of Health". It is composed of 20 herbs: Bupleurum, Angelica, White Peony, Atractylodes, Poria, Licorice, Cyperus (fried with vinegar), Aucklandia, Green Peel (fried with vinegar), Tangerine Peel, Amomum, Magnolia (fried with ginger), Citrus Aurantium (fried with bran), Curcuma, Chuanxiong, Crataegus (fried), Liushenqu (fried with bran), Pinellia, Gardenia (fried with ginger), Scutellaria, which has the effects of soothing the liver and relieving depression, relieving qi and relieving bloating. It is used for chest and flank pain caused by liver depression and qi stagnation, abdominal distension, acid regurgitation, and loss of appetite.
[0003] The Jieyuhegan pills prescription consists of 20 herbs with complex ingredients. The existing quality standards only have one microscopic identification and two thin layer identification items. The relevant literature also only has detection methods for some of the medicinal ingredients, which cannot fully reflect the product quality of the Jieyuhegan pills prescription preparations and cannot meet the needs of comprehensive quality control. Therefore, it is urgent to establish a method that can comprehensively and systematically detect the Jieyuhegan pills prescription preparations. Summary of the invention
[0004] Therefore, the technical problem to be solved by the present invention is to overcome the problem that the detection method of the Jieyuhegan pills prescription preparations in the prior art is unable to comprehensively and systematically detect the product quality of the Jieyuhegan pills prescription preparations, thereby providing a detection method of the Jieyuhegan pills prescription preparations and its use.
[0005] To this end, the present invention provides a method for detecting a Jieyuhegan pill prescription preparation, comprising the step of detecting a test solution by high performance liquid chromatography, wherein the chromatographic conditions of the high performance liquid chromatography include:
[0006] Octadecylsilane bonded silica gel was used as filler, acetonitrile was used as mobile phase A, and a phosphoric acid aqueous solution with a volume fraction of 0.05-0.15% was used as mobile phase B for gradient elution. The gradient elution procedure included:
[0007] 0→(20~25)min, the volume percentage of mobile phase A is 6~10%→16~20%;
[0008] (20-25) → 30 min, the volume percentage of mobile phase A is 16-20% → 21-25%;
[0009] 30→35min, the volume percentage of mobile phase A is 21~25%→26~30%;
[0010] 35→40min, the volume percentage of mobile phase A is 26~30%→30~34%;
[0011] 40→50min, the volume percentage of mobile phase A is 30~34%→38~42%;
[0012] 50→80min, the volume percentage of mobile phase A is 38~42%→68~72%.
[0013] Optionally, the gradient elution procedure comprises:
[0014] 0→20min, the volume percentage of mobile phase A is 6%→16%;
[0015] 20→30min, the volume percentage of mobile phase A is 16%→21%;
[0016] 30→35min, the volume percentage of mobile phase A is 21%→26%;
[0017] 35→40min, the volume percentage of mobile phase A is 26%→30%;
[0018] 40→50min, the volume percentage of mobile phase A is 30%→38%;
[0019] 50→80min, the volume percentage of mobile phase A is 38%→68%;
[0020] or,
[0021] 0→25min, the volume percentage of mobile phase A is 8%→18%;
[0022] 25→30min, the volume percentage of mobile phase A is 18%→23%;
[0023] 30→35min, the volume percentage of mobile phase A is 23%→28%;
[0024] 35→40min, the volume percentage of mobile phase A is 28%→32%;
[0025] 40→50min, the volume percentage of mobile phase A is 32%→40%;
[0026] 50→80min, the volume percentage of mobile phase A is 40%→70%;
[0027] or,
[0028] 0→20min, the volume percentage of mobile phase A is 10%→20%;
[0029] 20→30min, the volume percentage of mobile phase A is 20%→25%;
[0030] 30→35min, the volume percentage of mobile phase A is 25%→30%;
[0031] 35→40min, the volume percentage of mobile phase A is 30%→34%;
[0032] 40→50min, the volume percentage of mobile phase A is 34%→42%;
[0033] 50→80min, the volume percentage of mobile phase A is 42%→72%.
[0034] Optionally, the chromatographic conditions of the high performance liquid chromatography method further include at least one of the following:
[0035] 1) Flow rate is 0.8~1.2mL / min;
[0036] 2) Column temperature is 25-35°C;
[0037] 3) The injection volume is 5 to 15 μL;
[0038] 4) The detection wavelength is 225-235 nm and / or 280 nm;
[0039] 5) The chromatographic column is Shim-pack VP-ODS 5μm, 4.6×250mm.
[0040] Optionally, the preparation process of the test solution includes: taking the test sample, adding a solvent, extracting, separating the solid from the liquid, and taking the liquid;
[0041] Optionally, the solvent includes methanol and / or a methanol aqueous solution, and the volume percentage of methanol in the methanol aqueous solution is not less than 70%;
[0042] Optionally, the amount of the solvent added is 50 to 100 mL relative to 0.5 to 1.0 g of the test sample;
[0043] Optionally, the extraction is reflux extraction, and the reflux time is 1 to 3 hours.
[0044] Optionally, the preparation process of the test solution may include: taking 0.5-1.0g of the test sample, grinding it, accurately weighing it, placing it in a 100mL stoppered conical flask, accurately adding 50-100mL of the solvent, weighing the weight, reflux extraction (water bath temperature 80-85°C) for 1-3 hours, taking it out, cooling it, weighing it again, making up the lost weight with the solvent, shaking it well, filtering it, and taking the filtrate to obtain the test solution.
[0045] Optionally, the detection method further comprises the steps of preparing a reference solution using a gardeniain reference substance, a paeoniflorin reference substance, a naringin reference substance, a hesperidin reference substance, a neohesperidin reference substance and a baicalin reference substance, and detecting the reference solution using the high performance liquid chromatography method.
[0046] Optionally, the preparation process of the reference solution may include: taking appropriate amounts of gardeniain reference substance, paeoniflorin reference substance, naringin reference substance, hesperidin reference substance, neohesperidin reference substance, and baicalin reference substance, adding the solvent to prepare a reference mixed solution containing 58-86 μg of gardeniain, 26-38 μg of paeoniflorin, 10-15 μg of naringin, 58-86 μg of hesperidin, 10-15 μg of neohesperidin, and 29-43 μg of baicalin per 1 ml, respectively, to obtain the reference solution.
[0047] The present invention also provides the use of the above-mentioned detection method in the quality control and / or content determination of the Jieyuhegan pills prescription preparation.
[0048] The present invention also provides a quality control method for the Jieyuhegan pills prescription preparation, the quality control method comprising the steps of obtaining a fingerprint of the Jieyuhegan pills prescription preparation to be tested according to the above-mentioned detection method, and comparing the fingerprint with a control fingerprint;
[0049] Among them, the control fingerprint is obtained by fitting the fingerprint software using at least three batches of test samples of the Jieyuhegan pill prescription preparation according to the above-mentioned detection method.
[0050] Optionally, the control fingerprint spectrum includes 21 characteristic peaks, wherein peak 8 is used as the reference peak, and the relative retention time of each characteristic peak and the reference peak is within the range of ±5% of the specified value, the specified value of peak 1 is 0.42, the specified value of peak 2 is 0.53, the specified value of peak 3 is 0.67, the specified value of peak 4 is 0.83, the specified value of peak 5 is 0.94, the specified value of peak 6 is 0.95, the specified value of peak 7 is 0.98, the specified value of peak 9 is 1.01, and the specified value of peak 1 is 0. The prescribed value of peak 0 is 1.03, the prescribed value of peak 11 is 1.10, the prescribed value of peak 12 is 1.17, the prescribed value of peak 13 is 1.24, the prescribed value of peak 14 is 1.40, the prescribed value of peak 15 is 1.50, the prescribed value of peak 16 is 1.62, the prescribed value of peak 17 is 1.90, the prescribed value of peak 18 is 1.92, the prescribed value of peak 19 is 1.94, the prescribed value of peak 20 is 1.98, and the prescribed value of peak 21 is 2.02;
[0051] Optionally, peak No. 2 is the gardenia glycoside peak, peak No. 3 is the paeoniflorin peak, peak No. 4 is the ferulic acid peak, peak No. 7 is the naringin peak, peak No. 8 is the hesperidin peak, peak No. 10 is the neohesperidin peak, peak No. 11 is the baicalin peak, peak No. 13 is the wogonin peak, peak No. 14 is the baicalein peak, peak No. 15 is the glycyrrhizic acid peak, peak No. 16 is the wogonin peak, peak No. 17 is the honokiol peak, peak No. 19 is the costunol peak, peak No. 20 is the dehydrocostunol peak, and peak No. 21 is the magnolol peak.
[0052] Optionally, among the above 21 characteristic peaks, peaks 1, 2 and 9 are from Gardenia jasminoides, peaks 3 and 5 are from white peony root, peaks 4 and 18 are from Angelica sinensis and Ligusticum chuanxiong, peaks 6, 8 and 12 are from dried tangerine peel and green tangerine peel, peaks 7 and 10 are from Citrus aurantium, peaks 11, 13, 14 and 16 are from Scutellaria baicalensis, peak 15 is from Licorice, peaks 17 and 21 are from Magnolia officinalis, and peaks 19 and 20 are from Costusroot.
[0053] The present invention also provides a method for determining the content of the Jieyuhegan pills prescription preparation, which comprises the step of determining the content of gardenia glycoside, paeoniflorin, naringin, hesperidin, neohesperidin and baicalin in the Jieyuhegan pills prescription preparation to be tested according to the above-mentioned detection method.
[0054] Optionally, when the content of the Jieyuhegan pills prescription preparation to be tested is measured, the measurement wavelength of the gardeniain and the paeoniflorin is 230nm, and the measurement wavelength of the naringin, the hesperidin, the neohesperidin and the baicalin is 280nm.
[0055] Optionally, the dosage form of the Jieyuhegan pill prescription preparation includes at least one of pills, tablets, capsules, granules, honey pills, sustained-release preparations, immediate-release preparations, controlled-release preparations, and oral liquid preparations. Among them, the Jieyuhegan pill prescription preparation refers to various preparations prepared by taking each raw material according to the record of the Jieyuhegan pill prescription and according to the conventional preparation method in the field. The Jieyuhegan pill prescription is composed of 20 medicines including Bupleurum, Angelica, White Peony, Atractylodes, Poria, Licorice, Cyperus (fried with vinegar), Aucklandia, Green Peel (fried with vinegar), Tangerine Peel, Amomum, Magnolia Bark (fried with ginger), Citrus Aurantium (fried with bran), Curcuma, Chuanxiong, Crataegus (fried), Liushenqu (fried with bran), Pinellia, Gardenia (fried with ginger), and Scutellaria.
[0056] The technical solution of the present invention has the following advantages:
[0057] 1. The detection method of the Jieyuhegan pills prescription preparation provided by the present invention uses octadecylsilane bonded silica gel as a filler, acetonitrile as a mobile phase A, and a phosphoric acid aqueous solution with a volume fraction of 0.05-0.15% as a mobile phase B, and selects a specific elution procedure to overcome the interference caused by the complex chemical components of traditional Chinese medicine in the preparation, and can separate 21 common characteristic peaks, which not only significantly increases the number of characteristic peaks, but also achieves a good separation of these common characteristic peaks. The elution procedure of this method is simple, the baseline of the characteristic spectrum obtained is stable, the peak shape of each characteristic peak is good, and the separation degree between each characteristic peak is high. Therefore, the detection method can effectively improve the accuracy of the Jieyuhegan pills prescription preparation fingerprint spectrum, and the detection result can comprehensively and systematically reflect the integrity and characteristic of the Jieyuhegan pills prescription preparation, which is conducive to more comprehensive and systematic monitoring of the quality of the Jieyuhegan pills prescription preparation products.
[0058] 2. The detection method of the Jieyuhegan pills prescription preparation provided by the present invention adopts a specific test sample solution preparation method, and optimizes the extraction solvent, extraction method, extraction time, extraction sample dosage and other factors through multiple experiments to ensure that each active ingredient in the Jieyuhegan pills prescription preparation can be fully and sufficiently extracted, thereby obtaining more comprehensive active ingredient information, which can further improve the accuracy of the Jieyuhegan pills prescription preparation fingerprint, and facilitate more comprehensive and systematic monitoring of the quality of the Jieyuhegan pills prescription preparation.
[0059] 3. The detection method of the Jieyuhegan pills prescription preparation provided by the present invention, the chromatogram of the test sample obtained by detection can be used for fingerprint spectrum detection and multi-component content detection at the same time, which can significantly improve the speed and efficiency of the quality detection of the Jieyuhegan pills prescription preparation, and is conducive to saving analysis time and analysis costs; at the same time, the detection method also has the advantages of strong specificity, good stability, high precision, good repeatability, high accuracy, and easy to master.
[0060] 4. The quality control method for the Jieyuhegan pills prescription preparation provided by the present invention contains 21 characteristic peaks in the fingerprint spectrum detected, and 15 of the characteristic peaks are accurately located and identified, providing a basis for the quality control of the Jieyuhegan pills prescription preparation.
[0061] 5. The content determination method of the Jieyuhegan pills prescription preparation provided by the present invention can simultaneously determine the contents of 6 components in the Jieyuhegan pills prescription preparation, including gardenia glycoside, paeoniflorin, naringin, hesperidin, neohesperidin and baicalin. Compared with the content determination of a single component, this method can more quickly, comprehensively and systematically detect the quality of the Jieyuhegan drug preparation. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0063] Figure 1 It is the chromatogram of three batches of Jieyuhegan pills test products in Example 1 of the present invention;
[0064] Figure 2 It is the control fingerprint of Jieyuhegan pill determined in Example 1 of the present invention;
[0065] Figure 3 is the detection result of the common characteristic peak identification in Example 1 of the present invention;
[0066] Figure 4 is the detection result of the attribution of the common characteristic peaks in Example 1 of the present invention;
[0067] Figure 5 It is the verification result of the specificity of the fingerprint determination in Example 2 of the present invention;
[0068] Figure 6 It is the repeatability verification result of the fingerprint spectrum determination in Example 2 of the present invention;
[0069] Figure 7 It is the stability verification result of the test solution determined by the fingerprint in Example 2 of the present invention;
[0070] Figure 8 is the detection result of the mobile phase gradient elution procedure 1 in Example 2 of the present invention;
[0071] Fig. 9 is the detection result of the mobile phase gradient elution procedure 2 in Example 2 of the present invention;
[0072] Fig.10 is the detection result of the mobile phase gradient elution procedure 3 in Example 2 of the present invention;
[0073] Fig.11 is the detection result of the mobile phase gradient elution procedure 4 in Example 2 of the present invention;
[0074] Fig.12 is the detection result of the mobile phase gradient elution procedure 5 in Example 2 of the present invention;
[0075] Fig.13 is the detection result of the mobile phase gradient elution procedure 6 in Example 2 of the present invention;
[0076] Fig.14 is the investigation result of the phosphoric acid concentration in the mobile phase B in Example 2 of the present invention;
[0077] Fig.15 It is the investigation result of the flow rate in Example 2 of the present invention;
[0078] Fig.16 It is the investigation result of column temperature in Example 2 of the present invention;
[0079] Fig.17 This is the result of the sample weighing investigation in Example 2 of the present invention;
[0080] Fig.18 It is a chromatogram of the Jieyuhegan pill test sample in the comparative example of the present invention. DETAILED DESCRIPTION
[0081] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.
[0082] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.
[0083] The instruments, reagents and reagents involved in the embodiments of the present invention are as follows:
[0084] Shimadzu LC-20A series liquid chromatograph (vacuum degasser, low-pressure quaternary pump, autosampler, column oven, SPD detector); analytical balance, model: Mettler Toledo PL203 and XS205; water bath (TD digital display regulator); KQ-300DB digital control ultrasonic cleaner (300W, 40kHz).
[0085] Phosphoric acid (AR), Lot: 20211011, manufacturer: Sinopharm Chemical Reagent Co., Ltd.; Methanol (AR), Lot: 20220119, manufacturer: Sinopharm Chemical Reagent Co., Ltd.; Acetonitrile (HPLC), Lot: SHBP1347, manufacturer: Merk Company; Water, purified water.
[0086] Jieyuhegan Pills, batch numbers: 1907-60001, 1907-60002, 1907-60003, source: Beijing Tongrentang Pharmaceutical Co., Ltd.
[0087] Gardenia glycoside reference substance (purity: 97.1%, batch number: 110749-201919), paeoniflorin reference substance (purity: 95.1%, batch number: 110736-201943), ferulic acid reference substance (purity: 99.0%, batch number: 110773-201614), naringin reference substance (purity: 93.4%, batch number: 110722-20171 4), hesperidin reference substance (purity: 95.3%, batch number: 110721-202019), neohesperidin reference substance (purity: 99.2%, batch number: 111857-201703), baicalin reference substance (purity: 95.4%, batch number: 110715-201821), wogonin reference substance (purity: 98.5%, batch number: 112002-2 01702), baicalein reference substance (purity: 98.5%, batch number: 111595-201607), ammonium glycyrrhizinate reference substance (purity: 96.2%, batch number: 110731-202021), wogonin reference substance (purity: 100%, batch number: 111514-201605), honokiol reference substance (purity: 99.8%, batch number: 110 730-201915), costunolide reference substance (purity: 99.9%, batch number: 111524-201911), dehydrocostuslactone reference substance (purity: 99.5%, batch number: 111525-201912), and magnolol reference substance (purity: 99.0%, batch number: 110729-202015) were all purchased from China Food and Drug Inspection Institutes.
[0088] Example 1
[0089] Testing method of Jieyuhegan Pills (batch numbers: 1907-60001, 1907-60002, 1907-60003):
[0090] (1) Preparation of reference solution: Take appropriate amount of gardeniain reference, paeoniflorin reference, naringin reference, hesperidin reference, neohesperidin reference, and baicalin reference, weigh accurately, add methanol to dissolve, and prepare reference solution containing 72 μg gardeniain, 32 μg paeoniflorin, 12 μg naringin, 72 μg hesperidin, 12 μg neohesperidin, and 36 μg baicalin per 1 ml.
[0091] (2) Preparation of test solution: Take an appropriate amount of the product, grind it into powder, take about 0.75 g, weigh it accurately, place it in a stoppered conical flask, accurately add 50 ml of 80% methanol water, weigh it, reflux (water bath temperature 80°C) for 1 hour, take it out, cool it, weigh it again, make up the lost weight with 80% methanol water, shake it well, filter it, and take the filtrate to obtain the solution.
[0092] (3) Chromatographic conditions: Chromatographic column: Shim-pack VP-ODS 5μm, 4.6×250mm; acetonitrile as mobile phase A, 0.1% by volume phosphoric acid aqueous solution as mobile phase B, gradient elution as specified in Table 1; fingerprint detection wavelength of 230nm; content detection wavelength: 230nm (gardenia glycosides, paeoniflorin), 280nm (naringin, hesperidin, neohesperidin, baicalin); flow rate of 1mL / min; column temperature of 30°C; the number of theoretical plates calculated for hesperidin and baicalin should not be less than 5000.
[0093] Table 1 Gradient elution table
[0094]
[0095] (4) Determination method: Accurately pipette 10 μl of the reference solution and 10 μl of the test solution respectively, inject into the liquid chromatograph, and determine.
[0096] (5) Fingerprint determination results
[0097] ① Determination of common characteristic peaks and relative retention times
[0098] There are 21 common characteristic peaks in the chromatograms of the three batches of Jieyuhegan pills, such as Figure 1 shown. Figure 1 In the three test results, the corresponding drug batches from bottom to top are 1907-60001, 1907-60002, and 1907-60003. Peak 8 in the test results of each batch was used as the reference peak (S), and the relative retention time and relative peak area of the remaining peaks were calculated, and the average value and RSD% value were calculated respectively. The results are shown in Table 2.
[0099] Table 2 Relative retention time, relative peak area and matching number of each peak in three batches of test samples
[0100]
[0101]
[0102] ② Determination of reference fingerprints and formulation of similarity evaluation standards
[0103] The fingerprints of the three batches of samples were evaluated for similarity using the software "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System, 2012 Edition" recommended by the Pharmacopoeia Commission ( Figure 1 ), the median method was selected as the control fingerprint generation method, the time width was 0.1min, and the multi-point correction method was used to automatically match and generate the control fingerprint as the control fingerprint of Jieyu and Gan Wan, such as Figure 2 shown.
[0104] exist Figure 2 In the control fingerprint shown, there are 21 common characteristic peaks, among which peak No. 2 is the gardenia glycoside peak, peak No. 3 is the paeoniflorin peak, peak No. 4 is the ferulic acid peak, peak No. 7 is the naringin peak, peak No. 8 is the hesperidin peak, peak No. 10 is the neohesperidin peak, peak No. 11 is the baicalin peak, peak No. 13 is the wogonin peak, peak No. 14 is the baicalein peak, peak No. 15 is the glycyrrhizic acid peak, peak No. 16 is the wogonin peak, peak No. 17 is the honokiol peak, peak No. 19 is the costunol peak, peak No. 20 is the dehydrocostus lactone peak, and peak No. 21 is the magnolol peak.
[0105] Figure 1 The fingerprints of the three batches of samples are Figure 2 The similarity values of the reference fingerprints are all higher than 0.990, so the similarity evaluation criteria between the test sample fingerprint and the reference fingerprint are determined as follows:
[0106] According to the similarity evaluation system of Chinese medicine chromatographic fingerprint, the similarity between the test sample fingerprint and the reference fingerprint shall not be less than 0.90, and the peak 8 in the test sample fingerprint is used as the reference peak. The relative retention time of each characteristic peak and the reference peak is within the range of ±5% of the specified value, which is: peak 1 0.42, peak 2 0.53, peak 3 0.67, peak 4 0.83, peak 5 0.94, peak 6 Peak No. 1 is 0.95, Peak No. 7 is 0.98, Peak No. 8 is 1.00, Peak No. 9 is 1.01, Peak No. 10 is 1.03, Peak No. 11 is 1.10, Peak No. 12 is 1.17, Peak No. 13 is 1.24, Peak No. 14 is 1.40, Peak No. 15 is 1.50, Peak No. 16 is 1.62, Peak No. 17 is 1.90, Peak No. 18 is 1.92, Peak No. 19 is 1.94, Peak No. 20 is 1.98, and Peak No. 21 is 2.02.
[0107] ③ Identification of common characteristic peaks
[0108] The compound name corresponding to each characteristic peak was identified by the reference substance. Gardenia glycoside reference substance, paeoniflorin reference substance, ferulic acid reference substance, naringin reference substance, hesperidin reference substance, neohesperidin reference substance, baicalin reference substance, wogonin reference substance, baicalin reference substance, ammonium glycyrrhizinate reference substance, wogonin reference substance, honokiol reference substance, costus lactone reference substance, dehydrocostus lactone reference substance, and magnolol reference substance were respectively prepared into a single reference substance solution with a content of 0.1 mg / ml using methanol, and then the Jieyuhegan Pills (batch number: 1907-60001) test solution was taken and tested according to the chromatographic conditions of step (3) and the method of step (4). The test results are as follows: Figure 3 shown.
[0109] exist Figure 3 In the table, from bottom to top, the test results correspond to the Jieyuhegan Pills test sample (batch number: 1907-60001), gardenia glycoside reference substance, paeoniflorin reference substance, ferulic acid reference substance, naringin reference substance, hesperidin reference substance, neohesperidin reference substance, baicalin reference substance, wogonin reference substance, baicalin reference substance, ammonium glycyrrhizinate reference substance, wogonin reference substance, honokiol reference substance, costunolide reference substance, dehydrocostuslactone reference substance and honokiol reference substance.
[0110] The retention time of each corresponding chromatographic peak in the chromatograms of each reference substance and test substance was counted separately, as shown in Table 3.
[0111] Table 3 Retention time of corresponding peaks in the chromatograms of reference and test products
[0112]
[0113]
[0114] Depend on Figure 3 As can be seen from Table 3, the chromatograms of the test solution all have chromatographic peaks with the same retention time as the single reference substance in the chromatogram of the reference solution, and the spectra of the corresponding chromatographic peaks Figure 1 The compound names corresponding to the peaks in the chromatogram of the test sample can be confirmed.
[0115] ④ Attribution of common characteristic peaks
[0116] According to the prescription of Jieyuhegan Pills, negative test samples lacking Gardenia, lacking White Peony Root, lacking Angelica and Chuanxiong, lacking Tangerine Peel, lacking Citrus aurantium, lacking Citrus Aurantium, lacking Scutellaria, lacking Licorice, lacking Magnolia Bark, and lacking Costus Root were prepared in sequence. Then, negative test sample solutions were prepared according to the method described in step (2), and negative test sample solutions and Jieyuhegan Pills (batch number: 1907-60001) test sample solution were taken and tested according to the chromatographic conditions of step (3) and the method of step (4). The test results are as follows: Figure 4 shown.
[0117] exist Figure 4 In the figure, from bottom to top, the test results correspond to the Jieyuhegan Pills sample (batch number: 1907-60001), missing Gardenia sample, missing White Peony sample, missing Tangerine peel sample, missing Citrus aurantium sample, missing Citrus aurantium sample, missing Green Peel sample, missing Scutellaria baicalensis sample, missing Licorice sample, missing Magnolia bark sample, missing Costus root sample, missing Angelica sinensis and Chuanxiong sample.
[0118] Depend on Figure 4 It can be seen that in the chromatogram of the test solution, peaks 1, 2 and 9 come from Gardenia jasminoides, peaks 3 and 5 come from white peony root, peaks 4 and 18 come from Angelica sinensis and Ligusticum chuanxiong, peaks 6, 8 and 12 come from dried tangerine peel and green tangerine peel, peaks 7 and 10 come from Citrus aurantium, peaks 11, 13, 14 and 16 come from Scutellaria baicalensis, peak 15 comes from Licorice, peaks 17 and 21 come from Magnolia officinalis, and peaks 19 and 20 come from Costusroot.
[0119] (6) Results of multi-component content determination
[0120] Take the recorded chromatograms of the reference solution and the test solution, and calculate the contents of gardenia glycoside and paeoniflorin at 230 nm, and the contents of naringin, hesperidin, neohesperidin and baicalin at 280 nm. The content determination results of the three batches of test samples are shown in Table 4.
[0121] Table 4 Content determination results of three batches of test samples
[0122]
[0123] Example 2
[0124] This example is used to verify the method of the present invention:
[0125] (1) Verification of fingerprint determination specificity
[0126] The test solution of Jieyuhegan Pills (batch number: 1907-60001) and blank solvent were tested according to the chromatographic conditions of step (3) and the method of step (4) in Example 1, respectively. The test results are as follows: Figure 5 shown. Figure 5In the figure, the bottom is the test result of the test solution, and the top is the test result of the blank solvent. Figure 5 It can be seen that the blank solvent has no interference with the detection result of the test solution, indicating that the detection method of the present invention has good specificity.
[0127] (2) Verification of repeatability of fingerprint determination
[0128] The same batch of Jieyuhegan pills (batch number: 1907-60001) was used to prepare 6 test sample solutions in parallel according to the method described in step (2) of Example 1, and the test solutions were respectively tested according to the chromatographic conditions of step (3) and the method of step (4) of Example 1. The test results are shown in FIG. Figure 6 shown.
[0129] Depend on Figure 6 It can be seen that there are 21 common characteristic peaks in the test results of the 6 test solutions. The 6 chromatograms were imported into the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System", and the matching number of each peak was 6, and the similarity was greater than 0.995. Taking the No. 8 hesperidin peak as the reference peak, the relative retention time and relative peak area of each common peak in the 6 chromatograms were calculated respectively, and the relative retention time average value, relative retention time RSD value, and relative peak area RSD value of each common peak were statistically analyzed. The statistical results are shown in Table 5.
[0130] It can be seen from Table 5 that among the six chromatograms, the relative retention time and relative peak area of each common peak and peak No. 8 have good repeatability, indicating that the method of the present invention has good repeatability and meets the detection requirements of the fingerprint spectrum.
[0131] Table 5 Statistical results of relative retention time and relative peak area in repeatability verification test
[0132]
[0133] (3) Fingerprint determination and verification of the stability of the test solution
[0134] Take the Jieyuhegan Pills test sample (batch number: 1907-60001), prepare the test solution according to the method described in step (2) of Example 1, and place it at room temperature. After 0, 3, 6, 9, 12, and 24 hours, sample injection and detection are performed according to the chromatographic conditions of step (3) and the method of step (4) of Example 1. The test results are as follows: Figure 7 As shown. Figure 7 In the figure, from bottom to top, the placement times corresponding to the test results are 0 hours, 3 hours, 6 hours, 9 hours, 12 hours, and 24 hours.
[0135] Depend on Figure 7It can be seen that the chromatograms of the test solution injected at the above 6 time points all showed 21 common peaks. The 6 chromatograms were imported into the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System", and the matching number of each peak was 6, and the similarity was greater than 0.995. The peak area average and peak area RSD value of the 21 common peaks in the 6 chromatograms were calculated respectively, and the statistical results are shown in Table 6.
[0136] It can be seen from Table 6 that the peak area RSD values of the 21 common peaks measured at the above 6 time points are all less than 5%, indicating that the test solution prepared by the present invention has good stability when stored at room temperature for 24 hours.
[0137] Table 6 Test solution stability verification test results (n = 6)
[0138]
[0139] (4) Linear relationship and range of content determination
[0140] Take appropriate amounts of gardenia glycoside, paeoniflorin, naringin, hesperidin, neohesperidin, and baicalin reference substances, accurately weigh them, add methanol to dissolve them, and prepare reference substance mixed solutions with certain concentration gradients. Take reference substance mixed solutions of different concentrations, and inject and test them according to the chromatographic conditions of step (3) and the method of step (4) in Example 1, respectively, to examine the linear relationship between the injection amount (μg) of each component and the corresponding peak area.
[0141] The results are shown in Table 7. The injection amount of gardenia glycosides, paeoniflorin, naringin, hesperidin, neohesperidin, and baicalin reference substances had a good linear relationship with the corresponding area, and the linear range of the injection amount of each component met the detection requirements.
[0142] Table 7 Results of investigation on linear relationship of each component
[0143]
[0144]
[0145] (5) Verification of the precision of content determination instruments
[0146] The same reference solution was injected 6 times continuously according to the chromatographic conditions of step (3) and the method of step (4) in Example 1, and the chromatogram was recorded to examine the peak area precision of each peak. The results are shown in Table 8. As can be seen from Table 8, for the same reference solution, the RSD values of each peak area after 6 consecutive injections were all <1%, indicating that the injection precision of the instrument was good.
[0147] Table 8 Results of the precision of each chromatographic peak area (n=6)
[0148]
[0149] (6) Verification of repeatability of content determination
[0150] The same batch of Jieyuhegan pills (batch number: 1907-60001) was used to prepare 6 test solutions in parallel according to the method described in step (2) of Example 1, and the chromatographic conditions of step (3) and the method of step (4) of Example 1 were respectively used for detection, and the chromatograms were recorded. The average content and RSD value of each component in the 6 test solutions were calculated, and the results are shown in Table 9. As can be seen from Table 9, the RSD values of the contents of each component in the 6 parallel test solutions were all less than 2.0%, indicating that the repeatability of the content determination method of the present invention is good.
[0151] Table 9 Results of repeatability test of content determination (n=6, unit: mg / g)
[0152]
[0153] (7) Verification of content determination recovery rate
[0154] Preparation of test solution: Take an appropriate amount of Jieyuheganwan test sample with a known content according to half of the standard sample amount, accurately weigh, and place in stoppered conical bottles, respectively, and add an appropriate amount of reference sample mixed solution according to high, medium and low concentrations, 3 portions each, to prepare the test solution. Accurately pipette the reference sample solution and each test sample solution, and detect according to the chromatographic conditions of step (3) and the method of step (4) in Example 1, record the chromatogram, and calculate the sample recovery rate of each component, and the results are shown in Table 10. It can be seen from Table 10 that the sample recovery rates of the six components at high, medium and low concentrations are all between 95% and 103%, which meets the requirements of the recovery rate limit, indicating that the accuracy of the method of the present invention is good.
[0155] Table 10 Verification results of content determination recovery rate (%)
[0156]
[0157] (8) Stability verification of the reference solution for content determination
[0158] A new reference solution was prepared according to the method of step (1) in Example 1, and placed at room temperature. The solution was tested according to the chromatographic conditions of step (3) and the method of step (4) in Example 1 at 0h, 3h, 2, 3, and 4 days after placement, and the chromatogram was recorded. The average value and RSD value of the peak area of each reference solution were calculated, and the results are shown in Table 11. As can be seen from Table 11, the RSD values of the peak areas of the reference solution in the five determination results were all less than 1.0% within 4 days of being placed at room temperature, which proves that the reference solution of the present invention has good stability within 4 days of being placed at room temperature.
[0159] Table 11 Results of stability test of reference substance solution (n=5)
[0160]
[0161] (9) Content determination and stability verification of test solution
[0162] The Jieyuhegan Pills test sample (batch number: 1907-60001) was taken, and the test solution was prepared according to the method described in step (2) of Example 1, and placed at room temperature. At 0, 3, 6, 9, 12, and 24 hours after placement, the sample was tested according to the chromatographic conditions of step (3) and the method of step (4) of Example 1, and the chromatogram was recorded. The content of each component was calculated, and the results are shown in Table 12. It can be seen from Table 12 that when the test solution was placed at room temperature for 24 hours, the RSD of the content of each component in the test results at 6 time points was less than 1.0%, which proves that the test solution of the present invention has good stability at room temperature for 24 hours.
[0163] Table 12 Assay results of stability test of test solution
[0164]
[0165] (10) Investigation of mobile phase gradient elution procedure
[0166] The Jieyuhegan pills sample (batch number: 1907-60001) was tested according to the method of steps (1)-(4) in Example 1, except that the gradient elution program used was as shown in Tables 13-18.
[0167] Table 13 Mobile phase gradient elution program 1
[0168]
[0169] Table 14 Mobile phase gradient elution program 2
[0170]
[0171] Table 15 Mobile phase gradient elution program three
[0172]
[0173] Table 16 Mobile phase gradient elution program 4
[0174]
[0175] Table 17 Mobile phase gradient elution program 5
[0176]
[0177] Table 18 Mobile phase gradient elution program VI
[0178]
[0179] Test results such as Figure 8-13 shown. Figure 8 The test results of the mobile phase gradient elution program 1 shown in Table 13 are as follows: Fig. 9 The test results of the mobile phase gradient elution program 2 shown in Table 14 are as follows: Fig.10 The test results of the mobile phase gradient elution program 3 shown in Table 15 are as follows: Fig.11 The test results of the mobile phase gradient elution program 4 shown in Table 16 are as follows: Fig.12 The test results of the mobile phase gradient elution program 5 shown in Table 17 are as follows: Fig.13 The results are shown in Table 18 using the mobile phase gradient elution program 6.
[0180] Depend on Figure 8-13 It can be seen that when the mobile phase gradient elution program shown in Tables 13-15 is used, the peak shape and separation of some chromatographic peaks are poor. When the mobile phase gradient elution program shown in Tables 16-18 is used, the peak shape and separation of each chromatographic peak meet the detection requirements.
[0181] (11) Investigation of phosphoric acid concentration in mobile phase B
[0182] The Jieyuhegan Pills (batch number: 1907-60001) were tested according to the method of steps (1) to (4) in Example 1, except that the mobile phase B used was a phosphoric acid aqueous solution with a volume fraction of 0.05%, 0.10% and 0.15%, respectively. The test results are shown in Table 1. Fig.14 As shown, Fig.14 From bottom to top, the concentrations of the phosphoric acid aqueous solution corresponding to the test results are 0.05%, 0.10% and 0.15%. Fig.14 It can be seen that when the phosphoric acid concentration in the phosphoric acid aqueous solution is 0.05%, 0.10% and 0.15%, respectively, there is no obvious difference in the peak shape and separation degree of each peak in the chromatogram.
[0183] When three mobile phases B were used, the detection content of each component in the same test solution was calculated respectively. The results are shown in Table 19. It can be seen that there is no significant difference in the detection results, indicating that the concentration of phosphoric acid in mobile phase B between 0.05% and 0.15% meets the detection requirements.
[0184] Table 19 Investigation results of phosphoric acid concentration in mobile phase B
[0185]
[0186] (12) Investigation of flow rate
[0187] The Jieyuhegan Pills test sample (batch number: 1907-60001) was tested according to the method of steps (1) to (4) in Example 1, except that the flow rates of the mobile phase used were 0.8 ml / min, 1.0 ml / min and 1.2 ml / min, respectively. The test results are shown in Figure 1. Fig.15 As shown, Fig.15 From bottom to top, the flow rates corresponding to the test results are 0.8ml / min, 1.0ml / min and 1.2ml / min. Fig.15 It can be seen that when the mobile phase flow rates are 0.8ml / min, 1.0ml / min and 1.2ml / min respectively, there is no obvious difference in the peak shape and separation degree of each peak in the chromatogram.
[0188] When using three flow rates, the detection content of each component in the same test solution was calculated respectively. The results are shown in Table 20. It can be seen that there is no obvious difference in the detection results, indicating that the mobile phase flow rate of 0.8 to 1.2 ml / min can be used for the detection of this product.
[0189] Table 20 Results of flow rate investigation
[0190]
[0191] (13) Investigation of column temperature
[0192] The Jieyuhegan Pills test sample (batch number: 1907-60001) was tested according to the method of steps (1) to (4) in Example 1, except that the column temperatures used were 25°C, 30°C, and 35°C, respectively. The test results are shown in Table 1. Fig.16 As shown, Fig.16 From bottom to top, the column temperatures corresponding to the test results are 25℃, 30℃, and 35℃. Fig.16 It can be seen that when the column temperatures are 25°C, 30°C, and 35°C, respectively, there is no obvious difference in the peak shape and separation of the peaks in the chromatogram.
[0193] When using three column temperatures, the detection content of each component in the same test solution was calculated respectively. The results are shown in Table 21. It can be seen that there is no obvious difference in the test results, indicating that column temperatures of 25℃~35℃ can be used for the detection of this product.
[0194] Table 21 Investigation results of column temperature
[0195]
[0196] (14) Investigation of extraction solvent
[0197] Take the same batch of Jieyuhegan Pills (batch number: 1907-60001), use 70%, 80%, 90% methanol water and 100% methanol as solvents, ultrasonic extraction (300W, 40kHz) for 60 minutes, and prepare four test solutions. Take each test solution, and detect it according to the method of steps (3)-(4) in Example 1, and calculate the content of each component in each test solution. The results are shown in Table 22. It can be seen that the average total content of each component in the four test solutions is 18.893 mg / g, and the RSD value of the total content of each component between the four test solutions is 2.0%. Therefore, 70% to 100% methanol can be used as the extraction solvent for this product.
[0198] Table 22 Investigation results of extraction solvents for test samples (mg / g)
[0199]
[0200] (15) Investigation of extraction method and extraction time
[0201] Take the same batch of Jieyuhegan Pills (batch number: 1907-60001), accurately weigh 1.0g, weigh eight portions in parallel, place them in stoppered conical flasks, use 80% methanol 50ml as solvent, ultrasonically extract (300W, 40kHz) for 20, 30, 40, 50, 60 minutes and reflux (water bath temperature 80°C) for 1, 2, 3 hours to prepare eight test solutions. Take each test solution and test it according to the method of steps (3)-(4) in Example 1, and calculate the content of each component in each test solution. The results are shown in Table 23.
[0202] It can be seen that the total content of the six components in the test solution obtained by reflux extraction is significantly higher than that in the test solution obtained by ultrasonic extraction, especially the difference in the content of hesperidin is more obvious, indicating that reflux extraction is helpful for the extraction of hesperidin; there is no significant difference in the test results of the three test solutions obtained by reflux extraction.
[0203] Table 23 Results of the extraction method and extraction time (mg / g)
[0204]
[0205]
[0206] (16) Inspection of sample weight
[0207] Take 0.5 g, 0.75 g, and 1.0 g of the same batch of Jieyuhegan Pills (batch number: 1907-60001), accurately weigh them, and place them in stoppered conical flasks. Add 50 ml of 80% methanol as solvent, reflux (water bath temperature 80°C) and extract for 1 hour to prepare three test solutions. Take each test solution and test it according to the method of steps (3)-(4) in Example 1. The test results are as follows: Fig.17 shown. Fig.17 From bottom to top, the sample weights corresponding to the test results are 0.5g, 0.75g, and 1.0g. Fig.17 It can be seen that when the sample weight is 0.5g~1.0g, each chromatographic peak in the chromatogram achieves a good separation effect.
[0208] Under the condition of three sample weights, the content of each component in the same batch of test samples was calculated respectively. The results are shown in Table 24. It can be seen that there is no significant difference in the content of each component and the total content.
[0209] Table 24 Results of sample weight investigation (mg / g)
[0210]
[0211] Comparative Example
[0212] The Jieyuhegan Pills (batch number: 1907-60001) were tested according to the following method:
[0213] (1) Reference solution: Take each single reference solution prepared in Example 1 and use it to locate each active ingredient on the chromatogram.
[0214] (2) Test solution: Take an appropriate amount of Jieyuhegan pills, grind them into powder, take out about 0.75 g, weigh it accurately, put it in a stoppered conical flask, add 50 ml of 80% methanol accurately, weigh it, reflux (water bath temperature 80°C) for 1 hour, take it out, cool it, weigh it again, make up the lost weight with 80% methanol, shake it well, filter it, and take the filtrate to obtain the test solution.
[0215] (3) HPLC chromatographic conditions:
[0216] Chromatographic column: Shim-pack VP-ODS 5μm, 4.6×250mm; acetonitrile as mobile phase A, 0.05% phosphoric acid aqueous solution as mobile phase B, diode array detector; detection wavelength 230nm; flow rate 1.0mL / min; column temperature: 30℃; injection volume 10μL; elution mode is gradient elution, elution conditions are: 0-5min, 3%-3%A; 5-10min, 3%-10%A; 10-15min, 10%-1 2%A; 15-25min, 12%-16%A; 25-30min, 16%-16%A; 30-50min, 16%-20%A; 50-55min, 20%-20% A; 55-75min, 20%-25%A; 75-85min, 25%-46%A; 85-90min, 46%-85%A; 90-100min, 85%-85%A.
[0217] (4) Determination method: Accurately pipette 10 μl of each single reference solution and 10 μl of the test solution, inject them into the liquid chromatograph respectively, and determine them.
[0218] (5) Measurement results: The measurement results are as follows: Fig.18 As shown, it can be seen that when the Jieyu and Ganwan pills are tested using the above chromatographic conditions, the common peaks No. 5 and No. 6 cannot be separated, the common peaks No. 9 and No. 10 are not completely separated, and the chromatographic peaks No. 16 to No. 21 are piled up, resulting in a poor separation effect.
[0219] The reason for the above detection results is that the above mobile phase elution program is: within 0→100 minutes, the ratio of acetonitrile to 0.05% phosphoric acid solution in the mobile phase is controlled at 3%:97%→85%:15% through a gradient program, but the ratio of acetonitrile in the mobile phase increases slowly between 0→75 minutes, which is 3%→25%, resulting in the active ingredients in Jieyuhegan Pills, gardenia glycoside, paeoniflorin, ferulic acid, naringin, hesperidin, neohesperidin, and baicalin eluting too slowly, while the ratio of acetonitrile in the mobile phase increases rapidly between 75→100 minutes, which is 25%→85%, resulting in the accumulation of chromatographic peaks of the active ingredients in Jieyuhegan Pills, baicalin, baicalein, glycyrrhizic acid, baicalein, magnolol, costus lactone, dehydrocostus lactone, and magnolol, and failing to achieve good separation.
[0220] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A method for detecting a prescription preparation of Jieyuhegan pills, characterized in that: The method comprises the steps of detecting the test solution by high performance liquid chromatography, wherein the chromatographic conditions of the high performance liquid chromatography include: Octadecylsilane bonded silica gel was used as filler, acetonitrile was used as mobile phase A, and a phosphoric acid aqueous solution with a volume fraction of 0.05-0.15% was used as mobile phase B for gradient elution. The gradient elution procedure included: 0→(20~25)min, the volume percentage of mobile phase A is 6~10%→16~20%; (20-25) → 30 min, the volume percentage of mobile phase A is 16-20% → 21-25%; 30→35min, the volume percentage of mobile phase A is 21~25%→26~30%; 35→40min, the volume percentage of mobile phase A is 26~30%→30~34%; 40→50min, the volume percentage of mobile phase A is 30~34%→38~42%; 50→80min, the volume percentage of mobile phase A is 38~42%→68~72%; The detection method comprises the steps of determining the contents of gardenia glycoside, paeoniflorin, naringin, hesperidin, neohesperidin and baicalin in the Jieyuhegan pill prescription preparation to be tested; The chromatographic column was Shim-pack VP-ODS 5 μm, 4.6 × 250 mm; The measurement wavelength of gardeniside and the paeoniflorin is 230nm, and the measurement wavelength of naringin, hesperidin, neohesperidin and baicalin is 280nm; The preparation process of the test solution comprises: taking the test sample, adding a solvent, extracting, separating the solid from the liquid, and taking the liquid; The solvent includes methanol and / or methanol aqueous solution, and the volume percentage of methanol in the methanol aqueous solution is not less than 70%; the extraction is reflux extraction; The detection method also includes the steps of preparing a reference substance solution by using a gardenia glycoside reference substance, a paeoniflorin reference substance, a naringin reference substance, a hesperidin reference substance, a neohesperidin reference substance and a baicalin reference substance, and detecting the reference substance solution by using the high performance liquid chromatography method.
2. The detection method according to claim 1, characterized in that: The gradient elution procedure includes: 0→20min, the volume percentage of mobile phase A is 6%→16%; 20→30min, the volume percentage of mobile phase A is 16%→21%; 30→35min, the volume percentage of mobile phase A is 21%→26%; 35→40min, the volume percentage of mobile phase A is 26%→30%; 40→50min, the volume percentage of mobile phase A is 30%→38%; 50→80min, the volume percentage of mobile phase A is 38%→68%; or, 0→25min, the volume percentage of mobile phase A is 8%→18%; 25→30min, the volume percentage of mobile phase A is 18%→23%; 30→35min, the volume percentage of mobile phase A is 23%→28%; 35→40min, the volume percentage of mobile phase A is 28%→32%; 40→50min, the volume percentage of mobile phase A is 32%→40%; 50→80min, the volume percentage of mobile phase A is 40%→70%; or, 0→20min, the volume percentage of mobile phase A is 10%→20%; 20→30min, the volume percentage of mobile phase A is 20%→25%; 30→35min, the volume percentage of mobile phase A is 25%→30%; 35→40min, the volume percentage of mobile phase A is 30%→34%; 40→50min, the volume percentage of mobile phase A is 34%→42%; 50→80min, the volume percentage of mobile phase A is 42%→72%.
3. The detection method according to claim 1, characterized in that: The chromatographic conditions of the high performance liquid chromatography also include at least one of the following: 1) Flow rate is 0.8-1.2 mL / min; 2) Column temperature is 25-35°C; 3) The injection volume is 5 to 15 μL.
4. The detection method according to any one of claims 1 to 3, characterized in that: Relative to 0.5-1.0 g of the test sample, the amount of the solvent added is 50-100 mL; Optionally, the reflux time is 1 to 3 hours.
5. The detection method according to any one of claims 1 to 3, characterized in that: The dosage form of the Jieyuhegan pill prescription preparation includes at least one of pills, tablets, capsules, granules, and oral liquid preparations.
6. Use of the detection method according to any one of claims 1 to 5 in the quality control and / or content determination of the Jieyuhegan pills prescription preparation.
7. The use according to claim 6, characterized in that The dosage form of the Jieyuhegan pill prescription preparation includes at least one of pills, tablets, capsules, granules, and oral liquid preparations.
8. A method for detecting a prescription preparation of Jieyuhegan pills, characterized in that: The detection method comprises the steps of obtaining a fingerprint of the Jieyuhegan pill prescription preparation to be tested according to any one of the detection methods of claims 1 to 5, and comparing the fingerprint with a control fingerprint; The control fingerprint is obtained by fitting the fingerprint software using at least three batches of test samples of the Jieyuhegan pills prescription preparation according to the detection method described in any one of claims 1 to 5.
9. The detection method according to claim 8, characterized in that: The control fingerprint spectrum includes 21 characteristic peaks, among which, taking peak 8 as the reference peak, the relative retention time of each characteristic peak and the reference peak is within the range of ±5% of the specified value, the specified value of peak 1 is 0.42, the specified value of peak 2 is 0.53, the specified value of peak 3 is 0.67, the specified value of peak 4 is 0.83, the specified value of peak 5 is 0.94, the specified value of peak 6 is 0.95, the specified value of peak 7 is 0.98, the specified value of peak 9 is 1.01, the specified value of peak 10 is 0. The prescribed value of peak 1 is 1.03, the prescribed value of peak 11 is 1.10, the prescribed value of peak 12 is 1.17, the prescribed value of peak 13 is 1.24, the prescribed value of peak 14 is 1.40, the prescribed value of peak 15 is 1.50, the prescribed value of peak 16 is 1.62, the prescribed value of peak 17 is 1.90, the prescribed value of peak 18 is 1.92, the prescribed value of peak 19 is 1.94, the prescribed value of peak 20 is 1.98, and the prescribed value of peak 21 is 2.02; Optionally, peak No. 2 is the gardenia glycoside peak, peak No. 3 is the paeoniflorin peak, peak No. 4 is the ferulic acid peak, peak No. 7 is the naringin peak, peak No. 8 is the hesperidin peak, peak No. 10 is the neohesperidin peak, peak No. 11 is the baicalin peak, peak No. 13 is the wogonin peak, peak No. 14 is the baicalein peak, peak No. 15 is the glycyrrhizic acid peak, peak No. 16 is the wogonin peak, peak No. 17 is the honokiol peak, peak No. 19 is the costunol peak, peak No. 20 is the dehydrocostunol peak, and peak No. 21 is the magnolol peak.
10. The detection method according to claim 8 or 9, characterized in that: The dosage form of the Jieyuhegan pill prescription preparation includes at least one of pills, tablets, capsules, granules, and oral liquid preparations.
Citation Information
Patent Citations
Method for detecting paeoniflorin content in Chinese medicinal depression relieving pellet for treating depression
CN101738437A
Quality control method of Shuganjieyu capsule
CN103529136A
